Zenas BioPharma, Inc.
ZBIO
$16.91
-$0.02-0.12%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -37.51% | -20.77% | -113.95% | -208.43% | -30.74% |
Total Depreciation and Amortization | -65.71% | -30.30% | 10.00% | 38.46% | 20.69% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 190.64% | 197.61% | 223.96% | 152.17% | -83.20% |
Change in Net Operating Assets | 0.04% | -229.03% | 17.17% | 191.54% | 286.14% |
Cash from Operations | -34.83% | -93.96% | -150.35% | -197.53% | -48.04% |
Capital Expenditure | 100.00% | 18.18% | -335.29% | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -320,731.43% | -392,054.55% | -21,870.59% | -- | -- |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 1,288.71% | 135.71% | 12,552.00% | -- | 1,027.27% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -99.03% | 116.12% | 3,606.00% | 1,069.90% | 1,615,709.09% |
Foreign Exchange rate Adjustments | -837.50% | -244.44% | 262.07% | -1,400.00% | -80.72% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -203.93% | -525.71% | -160.74% | 239.65% | 807.87% |